Could a medicine for weak bones also protect the brain? A large study from the University of Hong Kong found that older adults who took a common group of osteoporosis drugs were less likely to be diagnosed with Alzheimer’s disease or another dementia. Here is what the researchers found, what the study can and cannot tell us, and what it means if you or a loved one takes an osteoporosis medication.
What Did the Osteoporosis and Dementia Study Find?
Researchers looked at the medical records of 121,492 adults aged 60 and older in Hong Kong who had osteoporosis or a fragility fracture between 2005 and 2020. They compared people who took nitrogen-containing bisphosphonates with similar people who took no osteoporosis medication, and with people who took other osteoporosis drugs.
The lower risk was seen in both women and men, and in people with hip fractures. The study was published in July 2025 in Alzheimer’s & Dementia, the journal of the Alzheimer’s Association.
Which Osteoporosis Drugs Were Studied?
The study focused on nitrogen-containing bisphosphonates, a group of osteoporosis medicines that slow bone loss. About 80% of the people in this group took alendronate.
Alendronate (about 80%)IbandronateRisedronateZoledronate
DenosumabSalcatonin (calcitonin)Strontium ranelateTeriparatide (Forteo)
How Big Was the Effect?
The researchers estimated that about 48 people would need to take a bisphosphonate for five years to prevent one case of dementia. For any one person the difference is small, but across a large population of older adults it could add up.
Does This Mean Bisphosphonates Prevent Dementia?
No. This was an observational study, which means it looked back at medical records. It can show that two things are linked, but it cannot prove that the medication caused the lower dementia risk.
- Bisphosphonate users had fewer dementia diagnoses
- The link held in women, men and hip fracture patients
- Results stayed similar when checked several different ways
- Whether the drug itself lowered the risk
- Memory and thinking at the start of the study
- Bone density, exercise, education or supplements like vitamin D
Clinical trials that assign people to a medication at random are needed before anyone can say these drugs protect the brain.
Why Might Bone Medicines Affect the Brain?
Nitrogen-containing bisphosphonates block an enzyme in the body’s mevalonate pathway, the same pathway that cholesterol-lowering statins act on. Researchers have found higher levels of some products of this pathway in the brains of people with Alzheimer’s disease, and animal studies with alendronate have shown less brain inflammation and less amyloid buildup. These findings point to a possible link, but they have not been confirmed in people.
What About Other Osteoporosis Medications, Like Forteo?
The study grouped several different medicines together as “other osteoporosis drugs,” including teriparatide (Forteo) and denosumab. People who take these medicines often have different health needs, such as more severe osteoporosis, so they cannot be compared directly with bisphosphonate users. This study does not show that any of these medicines raises or lowers the risk of dementia on its own.
What Should Patients Do With This Information?
1. Don’t change your medication. Do not start, stop or switch an osteoporosis medicine based on this study. Each one is chosen for your bone health, fracture risk and medical history.
2. Ask your doctor. Bring this study to your next appointment and ask what it means for you.
3. Keep up brain-healthy habits. Stay active, manage blood pressure and blood sugar, stay socially connected and keep up with regular checkups.
Have questions about your osteoporosis medication or what it costs? A QuickRx patient navigator can help. Call (917) 830-2525.
“Studies like this give you good questions to bring to your next appointment. Your osteoporosis treatment is chosen to protect your bones, so talk with your doctor before making any change.”
Julia Kravtsova, PharmD, Pharmacy Director, QuickRx Specialty Pharmacy
References
- Sing CW, Chan KH, Chiu PKC, et al. Bisphosphonates and the risk of dementia in patients with osteoporosis or fragility fracture: A population-based study in Hong Kong. Alzheimer’s & Dementia. 2025;21(7):e70503.
- Alendronate. MedlinePlus, U.S. National Library of Medicine.
Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice. Do not start, stop or change any osteoporosis medication without talking to your doctor.
Research Disclaimer: The study described here is observational. It shows a link between osteoporosis medications and dementia diagnoses but does not prove that any medication prevents dementia. Results may not apply to every patient or population.
Brand Disclaimer: QuickRx Specialty Pharmacy is not affiliated with, endorsed by or sponsored by any manufacturer named in this article; brand names are used for identification only.
Written by: Paola Larrabure, Marketing Director, QuickRx Specialty Pharmacy
Medically Reviewed by: Julia Kravtsova, PharmD, Pharmacy Director, QuickRx Specialty Pharmacy
Last Updated: November 2026